Predictive Biomarkers and Personalized Medicine DefectiveMismatchRepair Status asaPrognosticBiomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

  2011influential reference
• Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

  2011cited by this paper
• Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.

  2010cited by this paper
• Microsatellite instability in colorectal cancer—the stable evidence

  2010cited by this paper
• Microsatellite instability in colorectal cancer.

  2010cited by this paper
• Immunogenic death of colon cancer cells treated with oxaliplatin

  2010cited by this paper
• Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

  2010cited by this paper
• Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

  2010cited by this paper
• An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers

  2010cited by this paper
• Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

  2010cited by this paper
• Genetic instability influences drug response in cancer cells.

  2010cited by this paper
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009cited by this paper
• DNA mismatch repair (MMR)‐dependent 5‐fluorouracil cytotoxicity and the potential for new therapeutic targets

  2009cited by this paper
• Platinum Resistance: The Role of DNA Repair Pathways

  2008cited by this paper
• Prognostic Significance of Metastatic Lymph Node Ratio in Node-Positive Colon Carcinoma

  2007cited by this paper
• 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems.

  2007cited by this paper
• The metastatic lymph node ratio predicts survival in colon cancer.

  2007cited by this paper
• Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

  2007influential reference
• Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors.

  2006cited by this paper
• Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

  2005cited by this paper
• DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage*

  2005cited by this paper
• Systematic review of microsatellite instability and colorectal cancer prognosis.

  2005cited by this paper
• Microsatellite Instability and Colorectal Cancer Prognosis

  2005cited by this paper
• Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004influential reference
• Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

  2004influential reference
• Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression

  2003cited by this paper
• Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.

  2002influential reference
• MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA*

  2002cited by this paper
• Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.

  2001cited by this paper
• Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.

  1999cited by this paper
• A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).

  1998cited by this paper
• Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.

  1998cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

  1997cited by this paper
• The role of DNA mismatch repair in platinum drug resistance.

  1996cited by this paper
• The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

  1993cited by this paper
• Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

  1993cited by this paper
• Hereditary Colorectal Cancer

  1990cited by this paper

• CORRELATIVE ANALYSIS OF PUTATIVE MOLECULAR PREDICTIVE FACTORS IN PATIENTS WITH CURATIVELY RESECTED STAGE III COLON CANCER , TREATED WITH ADJUVANT OXALIPLATIN-BASED CHEMOTHERAPY

  2014cites this paper